Wednesday, June 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 31 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 8062640

    High affinity human antibodies to PCSK9

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 22, 2011 · Expires Nov 17, 2031

    granted

  2. US 8048418

    Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 1, 2011 · Expires Oct 27, 2031

    granted

  3. US 8043617

    Human antibodies to human IL-6 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 25, 2011 · Expires Oct 20, 2031

    granted

  4. US 8029791

    Modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  5. US 8003103

    High affinity human antibodies to human IL-18 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 23, 2011 · Expires Aug 18, 2031

    granted

  6. US 7988967

    High affinity human antibodies to human nerve growth factor

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 2, 2011 · Expires Jul 28, 2031

    granted

  7. US 7972598

    VEGF-binding fusion proteins and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 5, 2011 · Expires Jun 30, 2031

    granted

  8. US 7964377

    Nucleic acid molecule encoding a fusion polypeptide capable of binding VEGF

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 21, 2011 · Expires Jun 16, 2031

    granted

  9. US 7927583

    Receptor based antagonists and methods of making and using

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 19, 2011 · Expires Apr 14, 2031

    granted

  10. US 7919593

    Human antibodies to human delta like ligand 4

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2011 · Expires Mar 31, 2031

    granted

  11. US 7879984

    Human antibodies to human CD20 and method of using thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 1, 2011 · Expires Jan 27, 2031

    granted

  12. US 7837999

    Method of increasing muscle mass with IGF-1 fusion polypeptides

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 23, 2010 · Expires Nov 18, 2030

    granted

  13. US 7820154

    Use of IL-1 antagonists to treat gout

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 26, 2010 · Expires Oct 21, 2030

    granted

  14. US 7807164

    Lyophilized VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 5, 2010 · Expires Sep 30, 2030

    granted

  15. US 7794717

    High affinity human antibodies to human IL-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 14, 2010 · Expires Sep 9, 2030

    granted

  16. US 7781404

    IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 24, 2010 · Expires Aug 19, 2030

    granted

  17. US 7732167

    Interferon-α/β binding fusion proteins and therapeutic uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 8, 2010 · Expires Jun 3, 2030

    granted

  18. US 7704500

    Methods of inhibiting ascites formation with modified chimeric VEGF polypeptides

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 27, 2010 · Expires Apr 22, 2030

    granted

  19. US 7655758

    Stable liquid IL-1 antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 2, 2010 · Expires Jan 28, 2030

    granted

  20. US 7635474

    VEGF-binding fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 22, 2009 · Expires Dec 17, 2029

    granted

  21. US 7632503

    Method of treating a muscle-related condition with modified IGF1 polypeptides

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 15, 2009 · Expires Dec 10, 2029

    granted

  22. US 7632490

    Use of IL-1 antagonists to treat gout

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 15, 2009 · Expires Dec 10, 2029

    granted

  23. US 7615220

    High affinity human antibodies to human IL-18 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 10, 2009 · Expires Nov 5, 2029

    granted

  24. US 7608261

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 27, 2009 · Expires Oct 22, 2029

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.